Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/10527
Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain
Identifiers
ISSN: 2164-5515
eISSN: 2164-554X
WOS ID: 000384217200021
Scopus EID: 2-s2.0-84978543516
PMID: 27184622
Embase PUI: L611287053
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2016Document type
research articleCitation
Garcia A, Ortiz De Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Human Vaccines Immunother. 2016;12(9):2269-77. Epub 2016 May 16.Abstract
Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748Euro/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis shows ICER below 30,000Euro/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.
Publisher version
https://dx.doi.org/10.1080/21645515.2016.1182275Keywords
costs and cost analysiscost-effectiveness analysis
human
healthcare costs
influenza
influenza B virus
influenza vaccines
QIV
vaccines
MeSH
ChildAged, 80 and over
Aged
Young Adult
Cost of Illness
Spain
Adult
Humans
Child, Preschool
Adolescent
Cost-Benefit Analysis
Middle Aged
Infant
Pregnancy
Influenza Vaccines
Male
Influenza, Human
Female
DeCS
FemeninoLactante
Análisis Costo-Beneficio
Gripe Humana
Adolescente
Vacunas contra la Influenza
Masculino
Preescolar
Humanos
Persona de Mediana Edad
Adulto Joven
Embarazo
Anciano
Anciano de 80 o más Años
Niño
Costo de Enfermedad
Adulto
España
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica